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Abstract
Drug delivery from 3-dimensional (3D) structures is a rapidly growing area of research. It is
essential to achieve structures wherein drug stability is ensured, the drug loading capacity is
appropriate and the desired controlled release profile can be attained. Attention must also be
paid to the development of appropriate fabrication machinery that allows 3D drug delivery
systems (DDS) to be produced in a simple, reliable and reproducible manner. The range of
fabrication methods currently being used to form 3D DDSs include electrospinning (solution
and melt), wet-spinning and printing (3-dimensional). The use of these techniques enables
production of DDSs from the macro-scale down to the nano-scale. This article reviews
progress in these fabrication techniques to form DDSs that possess desirable drug delivery
kinetics for a wide range of applications.
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Introduction
Drug delivery is the method or process of administering a pharmaceutical compound to
achieve a therapeutic effect in humans or animals. Drug delivery systems (DDSs) can provide
predetermined drug release profiles that ensure optimal distribution and absorption of drug to
improve efficacy and safety, providing patient convenience and assisting compliance. Current
efforts in the area of drug delivery include the development of targeted delivery (sometimes
called smart drug delivery) in which the drug is only active in the target area of the body [14] (for example, in cancerous tissues), and sustained release formulations in which the drug is
released over a period of time in a controlled manner from a formulation [5-7]. The materials
inventory for use in drug delivery, particularly in the areas of targeted delivery and controlled
delivery, continue to expand.

In parallel with developments in new materials for drug delivery, new material fabrication
tools and protocols have emerged. These advances provide an alternative means of
engineering release profiles by control of spatial distribution within a given polymer
composition rather than creating a new host material.

There is a growing interest towards the fabrication of three dimensional (3D) macro-, microor nanoscale systems made from thermoset, [8] or thermoplastic polymers, [9] hydrogels,
[10,11], powders, [12] or polyelectrolytes, [13] which may find potential applications in
complex microfluidic networks, [14,15] tissue engineering scaffolds, [16,17] and drug
delivery systems [18]. Several strategies have been employed to precisely assemble 3D
structures, including photolithographic, [19] colloidal-epitaxy, [20] and direct write
techniques. [21,22] Among these, direct-write is one of the most promising approaches as it
offers flexibility in material selection, low cost, and ability to construct complex 3D
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structures. [23] Direct-write assembly is a 3D printing technique which employs a computercontrolled translational stage that moves a pattern-generating device in order to achieve, layer
by layer, the desired 3D microstructure. This enables composition to be varied throughout the
3D structure giving a degree of control not available with traditional fabrication [24]
Different materials such as colloidal inks, [25,26] concentrated polyelectrolytes, [27] and
bioinks (e.g., hydrogels with suspended cells) [28,29] have been employed in this technique
to fabricate various microstructures for specific applications [30]. The added advantage of
these types of 3D DDSs is that it does not rely on the use of a mold to form the structure as is
the case for conventional DDSs such as tablets or inserts and devices that may be made from
injection molding methods. The fact that molds are not required for the direct write 3D
approach provides a high degree of flexibility in the structural design aspects of these direct
write 3D DDSs.

This review will provide insight into the rapidly growing area of fabricating 3D drug delivery
systems with a range of techniques such as wet-spinning, printing, melt extrusion and
electrospinning technologies. A recent review by Kolakovic, et al [31] comprehensively
detailed the use of 2-dimensional (2D) flexible roll-to-roll and inkjet printing technology to
produce drug delivery systems. Therefore this review presented here will not discuss this area
of research.

Wet-spinning drug loaded fibres
The wet-spinning technique (Figure 1a) uses polymers dissolved in a solvent (the spinning
dope). The spinneret is submerged in a chemical bath that is of a composition such that this
causes the fibre to precipitate, and then solidify, as it emerges. By incorporating a drug into
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the spinning dope it is possible to form a drug-loaded fibre. This approach has been utilised
for a number of pharmaceutical applications [32].

Figure 1
Wet-spinning process (a). SEM images of the cross-section of medicated
fibres with different HPMC contents: (b) 0 wt% and (c) 15 wt%. Cumulative TAM release
profiles (d) with varying amounts of HPMC added to PAN (0, 10, 20 and 30 wt%).
Experiments were carried out in triplicate and the results were reported as average values.
(Reproduced from reference [33] with permission)

Nie et al [34] prepared Tamoxifen citrate (TAM)-loaded polyacrylonitrile (PAN) fibres using
a wet-spinning technique. TAM was used as a model drug to evaluate the potential
application of the loaded fibre system for drug delivery. PAN was first homogeneously
dissolved in the N,N-dimethylacetamide (DMAc) solution containing TAM and then the codissolving solution was solidified to prepare the fibres using a wet-spinning method. The in
vitro release experiment indicated that constant drug release from the fibre was observed over
an extended period. Kinetic studies demonstrated that the system followed Higuchi kinetics.
They did observe that at the beginning of the experiment a larger amount of TAM is released
and concluded that this is possibly due to surface location and the physical binding of TAM
to the fibres. Shen et al [33] later showed that the incorporation of the hydrophilic polymer
hydroxypropyl methylcellulose (HPMC) with PAN reduced the initial burst release effects
and increased the drug-loading (Figure 1b, c and d). The drug-release profiles of HPMC/PAN
drug-loaded fibres were consistent and stable compared to those of the control PAN. With the
increased ratio of HPMC to PAN the drug-release profiles became more stable on account of
the hydrated viscous layer formed by HPMC in the composite fibres. The in vitro dissolution
results also reflected the effect of HPMC on modulating the release rate of TAM in the
composite fibres. A higher proportion of HPMC decreased the rate of drug release.
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The biodegradable polymer PLGA has also been used to form biofactor loaded fibres using a
wet-spinning process [35]. Crow et al [35] fabricated biodegradable fibres of poly(L-lactic
acid) (PLLA) and poly(D,L-lactide-co-glycolide) (PLGA) that encapsulated the protein
bovine serum albumin (BSA) using an approach that consisted of wet-spinning a water-in-oil
emulsion. They also studied the drug release kinetics and changes in molecular weight over
time. These fibres are 2.4% by mass of bioactive material, and showed slow release
properties. Release kinetics demonstrated that BSA release rates and molecular weight
degradation were influenced by the amount of aqueous phase added as an emulsion during
fabrication. They concluded that the type of polymer used (PLLA or PLGA) determines the
molecular weight degradation rates, but has little effect on drug release kinetics. This last
finding suggests that diffusion processes, as opposed to degradation rates, are the driving
force for BSA release from the degradable polymer structures.

More recently biodegradable PLGA fibres (diameters of 250–300 μm) were used for the
controlled delivery of dexamethasone or levofloxacin [36]. Mack et al [36] performed a
comprehensive study whereby the degradable polymer composition was varied (PLGA 75:25,
PLGA 50:50 and poly(d,l-lactide)- PDLLA) as was the drug type (dexamethasone (Dex) or
levofloxacin (Levo)) and loading (4.8 to 18.4 wt%). Their findings indicated several
important factors influencing drug release kinetics (Figure 2);
i.

Drug release could be controlled by drug loading (Figure 2a)

ii.

Drug release could be controlled by polymer type (Figure 2b), and

iii.

Dex released more slowly than Levo and that, upon increasing the Dex concentration,
release could be slowed (Figure 2c)

Figure 2
The release profiles of a) filaments containing levofloxacin, dissolved and
precipitated, PLGA 50:50, b) filaments made from different polymers, and c) filaments
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formulated with dexamethasone (PLGA 50:50 at Levo 7 wt% loading given in each panel for
comparison). Error bars represent one standard deviation (n=3). The table describes the wetspinning conditions for each fibre in the release graphs. (Figure reproduced from reference
[36] with permission, Table adapted from [36])

3-Dimensional (3D) Printing

3D printing is a process for making a three-dimensional solid object of virtually any shape
from a digital model. 3D printing is achieved using an additive process (Figure 3), where
successive layers of material are laid down in different shapes. 3D printing is also considered
distinct from traditional machining techniques, which mostly rely on the removal of material
by methods such as cutting or drilling (subtractive processes). While 3D printing technology
was introduced in the 1980s, only recently have printers become widely available
commercially.

So called “solution phase” 3D printing has been used to form macro- and micro- sized
structures for drug delivery. The final product often contains a number of structural and
bioactive (drug) components [37]. A significant challenge is the development of suitable
host/structural materials that can be processed using this technique.

Printing allows the deposition of precise quantities of structural/scaffolding materials and
therapeutic substances, [38,39] and is versatile enough to incorporate concentration gradients
and other spatial patterns of drug deposition within the polymer matrix. The versatility of 3D
printing in the biomedical area is demonstrated by Ferris et al [40] and Chung et al [41] who
published work on the development of extrusion printing of hydrogel structures loaded with
living cells. Many research teams have utilized this versatility of 3D printing to construct
6

tissue engineering structures that contain biofactors, such as growth factors, for use in bone
regeneration [42] and nerve repair. In these and many other publications detailing 3D printed
structures that contain biofactors, these structures were fabricated to support the growth of
desired cells with the incorporated factor present in order to facilitate growth. Rattanakit et al
[18] reported the use of a novel extrusion printing system to create drug delivery structures
wherein the drug dexamethasone-21-phosphate disodium salt (Dex21P) was encapsulated
within a biodegradable polymer (PLGA75:25) and water soluble poly(vinyl alcohol) (PVA)
configurations. The authors demonstrated the ability to control the drug release profile
through the spatial distribution of drug within the printed 3-dimensional structures (Figure 3).
The extrusion printing process was used to fabricate two different structural configurations
(Figure 3c and h) that demonstrated very different release profiles. This approach clearly
demonstrated that, through simply modifying the printing patterns and structure (whilst not
altering the polymer-drug “ink” properties), it is possible to modify the drug release
properties.

Figure 3
Schematic representation of the printed PVA–Dex21P on the PLGA drop cast
film: (a) top view, (b) side view and (c) scroll configuration. The drug release profiles (e),
loaded with different PVA molecular weight. The schematic representation (side view) of
PVA-Dex21P sandwiched between PLGA layers; (e) 1 layer system, (f) 2 layers system, and
(g) 3 layers system. The digital image of a 1 layer structure (h) shows the printed
PVA:Dex21P line (containing a small amount of violet dye for visualization) between PLGA
layers and (i) the drug release profiles from the different layer systems. (Reproduced from
reference [18] with permission)

Hot-melt extrusion Printing
There are diverse methods used to prepare drug-loaded solid dispersions using polymers and
other excipients meeting the requirements of the pharmaceutical industry. [43-47]. Another of
these methods is melt extrusion, a solvent-free continuous tool for dispersing active
pharmaceutical ingredients (APIs) in a polymeric matrix [47-50]. Extrusion is the process of
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forcing a raw material through a die, resulting in a product that is uniform in cross-sectional
shape (Figure 4) [51]. The shape of the hole in the die of the extrusion device dictates the
cross-sectional shape of the final product, and in fact almost any shape can be produced. The
raw material must have appropriate rheological properties to allow extrusion through the die.
This can be achieved by multiple methods, the most common being by melting, often referred
to as hot-melt extrusion (HME). This approach has been employed to produce polymer-based
rods [52], pellets [53] and fibres [54] loaded with therapeutic substances. Hot -melt extrusion
over recent years has found widespread application as a viable drug delivery option in the
drug development process and has been successfully applied to enable integration/distribution
of poorly soluble drugs [55-59].

Figure 4
Hot-melt extrusion (HME) equipment (a) used in the formation of drug loaded
rods, pellets and fibres. Hot-melt extrusion print head (b) and schematic (c) of the internal
polymer/drug loaded syringe encased in the heating block.

Drugs are incorporated into the polymer by mixing the raw polymer and drug materials in the
extrusion device before melting the polymer in a heated barrel. This results in one of several
potential molten phases: the drug may melt along with the polymer; the drug may dissolve in
the melted polymer; or the drug may be dispersed throughout the melted polymer. Drugs that
melt or dissolve in the molten polymer usually result in extruded products that demonstrate
molecular dispersions of the drug in the polymer matrix (termed glass dispersions) [60],
while drugs that are dispersed in molten phase usually remain dispersed as aggregates
throughout the polymer matrix after extrusion. The efficiency of melt extrusion to uniformly
distribute the drug evenly throughout the dosage form was investigated by Park et al [61].
Using a fluorescent dye as a model drug and employing confocal laser scanning microscope
(CLSM) imaging, they showed that model drugs were well distributed throughout the hot-
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melt extrudate, giving better content uniformity with low batch-to-batch variations compared
with simple physical mixtures.

A thorough understanding of the structure of a solid dispersion, particularly the existing
physical form of a drug in the carrier matrix is required to predict the stability, solubility and
hence bioavailability of melt extrudates [62]. Through the use of HME, Deng et al [63] were
able to improve the dissolution rate and enhance the stability of a poorly water-soluble and
low glass-transition temperature (Tg) model drug, fenofibrate, in low molecular weight
grades of hydroxypropylcellulose matrices. They showed that the dissolution rate of
fenofibrate from melt extruded pellets was faster than that of the pure drug (p < 0.05) and that
the incorporation of sugars within the formulation further increased the fenofibrate release
rates.

It is critical to effectively disperse the drug in a polymer matrix at the molecular level in
order to enhance its bioavailability as well as control its release. Nagy et al [50] utilized melt
extrusion and supercritical CO2-aided melt extrusion of solid pharmaceutical formulations to
enhance the dissolution rate of the poorly water soluble drug carvedilol, a nonselective beta
blocker/alpha-1 blocker indicated in the treatment of mild to severe congestive heart failure
(CHF) and high blood pressure. They found the presence of the drug had a plasticizer effect
of the polymer matrix (Eudragit E) and that the supercritical extrusion process did not
decompose the drug. When comparing melt extrusion, supercritical extrusion and physical
mixing methods it was shown that the extruded samples showed significantly improved
dissolution rates (Figure 5a) with the supercritical samples showing slightly more rapid
dissolution in the initial few minutes. This initial increase is attributed to an inner porosity of
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the supercritical sample due to its foaming (high porosity) nature (Figure 5c compared to
Figure 5b).

Figure 5
Dissolution profiles (a) of (i) supercritical melt extruded, (ii) melt extruded,
(iii) physical mix. Optical images of the melt extruded sample (b) and supercritical extruded
sample (c). (Reproduced from reference [50] with permission).

The main disadvantage of the melt extrusion technique is the high temperatures needed to
melt the polymer which prohibits the use of this method for therapeutic substances that are
especially heat labile. However, Stankovic et al [64] synthesised a low melting biodegradable
hydrophilic multiblock copolymer composed of poly (ethylene glycol) and poly (caprolactone) to allow extrusion at relatively low temperatures. They investigated the
extrusion characteristics of this polymer and explored a strategy for controlling the release of
the model protein lysozyme from small diameter extruded implants (Figure 6). It was found
that the polymer could be extruded at temperatures as low as 55 oC. Moreover, lysozyme
remained active both during extrusion as well as during release. This low temperature
processing is highly attractive for further developing delivery systems whereby the payload
of the printed structures is a biological molecule with poor thermal stability such as growth
factors.

Figure 6
The in vitro release of lysozyme in 100 mM phosphate buffer, pH 7.4 at 37 oC
for 260 days, (n = 3). The initial 24 h release (upper figure) is shown in hours. (Reproduced
from reference [64] with permission).

Dierickx et al [65] produced co-extrudates consisting of two concentric polymer matrices: a
core having a lipophilic character (ethylcellulose or poly (e-caprolactone)) and a coat with a
hydrophilic character (Soluplus or polyethylene oxide). Diclofenac sodium (DS) was
incorporated as the model drug in both layers. The maximum drug load in the core and coat
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depended on the extrusion temperature and the die dimensions, while adhesion between core
and coat was mainly determined by the drug load and by the extrusion temperature (Figure
7).

Figure 7
Mean dissolution profile (±SD) (n = 3) of experimental formulations () F1,
(X) F2, () F3, () F4 and (- - -) Motifene. The insert table shows the formulation
conditions. (Reproduced from reference [65] with permission).

The versatility of the HME process also provides a means to produce DDSs that possess
variable release kinetics. The release of melanotan-I (MT-I) from biodegradable implants of
poly(D,L lactide-co-glycolide) (PLGA; 50:50 molar ratio of lactic/glycolic acid) copolymer
produced by HME have been reported by Bharadwaj and Blanchard [66,67] . The in vitro
release of MT-I exhibited a triphasic profile with an initial rapid release (less than 5% of the
drug load) followed by a secondary phase of slow release. It was also observed that a tertiary
phase of rapid release commenced after about 3 weeks, due to erosion of the polymer. The
polymer erosion and degradation were considered as the factors influencing the drug release
and were controlled by the physical properties of the polymer, such as molecular weight and
viscosity.

The HME process described above has also been adapted to function as a 3D printer (Figure
8) whereby the polymer melt is extruded from a movable tip and a structure can be printed on
a moving x-y-z stage following a pre-designed structure shape; a process also referred to as
fused deposition modelling (FDM). The work undertaken by Masood [68] clearly
demonstrates the feasibility of using FDM to fabricate DDSs with varying drug release
characteristics. Masood demonstrated the ability of HME printed structures to modulate the
diffusion of drug (represented by model dyes) through the HME printed structures.
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Electrospinning
Among several methods for preparing bioactive loaded polymer structures for drug delivery,
the electrospinning technique presents a number of advantages; in particular, the possibility
of fabricating nanodimensional high specific surface area structures [69]. Electrospun fibres
have been successfully developed for the encapsulation and the delivery of bioactive
compounds for therapeutic treatments [70-74].

Typically drug enrichment at the surface of electrospun fibres occurs when the drug is
blended into a polymer solution prior to electrospinning, and results in severe burst release
phenomenon [75]. This burst release reduces the effective lifetime of the delivery device.

The development of coaxial electrospinning has gone some way towards improving drug
encapsulation efficiency and thus release profiles, and is a relatively new technique. Coaxial
electrospinning of core–shell fibres has added to the versatility of DDSs by affording a near
zero-order drug release kinetics, dampening of burst release, and applicability to a wider
range of bioactive agents. Controllable electrospinning of fibres and subsequent drug release
from these chiefly polymeric vehicles depend on well-defined solution and process
parameters. Viry et al [76] developed a novel technique combining coaxial and emulsion
electrospinning to produce microstructured core–shell fibres from the degradable polymer
PLGA. The structures were composed of a 75:25 PLGA core and an 85:15 PLGA shell, with
the drug (the antiepilepsy drug Leviteracetam - Lev) contained within the core PLGA
polymer. They demonstrated that when the core was formed from an emulsion of PLGA and
drug, the core morphology varied considerably compared to when the core was formed from
a solution of PLGA and drug. The coaxial-emulsion approach facilitated the design of drug
microreservoirs of variable size within the bulk of the fibre and, combined with a tailored
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diffusive barrier, allowed modulation of the release kinetics of these novel carriers. A nearly
constant and linear release of Levetiracetam from PLGA emulsion-coaxial electrospun fibres
was observed over 20 days (Figure 8).

Figure 8
Coaxial electrospun fibres consisting of PLGA 75:25 core and 85:15 sheath
observed by SEM (a and b). Coaxial fibre cores (a) were formed from a PLGA solution in
which Lev was blended and emulsion/coaxial fibre (b) cores were formed from a reverse
emulsion in which Lev was dispersed in the aqueous phase. Coaxial/emulsion (c)
configuration showing schematics of the corresponding fibre structures produced from each
method. Cumulative release (d) of Lev in artificial cerebrospinal fluid (aCSF) (37 oC, pH 6.8)
from coaxial () and emulsion/coaxial () electrospun fibres represented as drug amount
(Mt) released relative to drug loading (Mtot) of the carrier. Error bars represent standard errors
from the average calculated on three specimens. (Reproduced from Ref. [76] with permission
from The Royal Society of Chemistry)

The non-degradable polymer polyurethane (PU) has been used to form electrospun drug
delivery structures [77-79]. Han et al [80] fabricated electrospun PU fibres containing the
drug Rapamycin (RM). The RM-contained PU fibres, generated by three distinct blending
methods, exhibited significantly different fibre diameters (200–500 nm) and distinct RM
release kinetics. They found that as the concentration of RM increased, the electrospun fibre
diameter also increased and that the amount of RM released at each sample time point was
generally dependent on the amount of RM loading; but the release kinetics was not affected
by the amount of RM. They concluded that this suggests that RM localized on/near the fibre
surfaces accounted for the main sources of drug release within their 49 day release period.

Melt Electrospinning
Melt electrospinning (MES) is a promising technique to prepare fibrous drug-loaded
polymer-based solid dispersions for drug delivery systems with controlled release properties
without the use of solvents. The absence of solvent in MES has a number of potential
advantages. In particular, the risk of toxic solvent residue in the fibres can be eliminated;
13

making MES a preferred technique for tissue engineering [81-83] and oral drug delivery
purposes.

Melt electrospinning (MES) was used to prepare fast dissolving fibrous drug delivery systems
in the presence of plasticizers. Lowering of the process temperature was achieved by using
plasticizers in order to avoid undesired thermal degradation. Carvedilol (CAR), a poorly
water-soluble and thermal-sensitive model drug, was introduced into an amorphous
methacrylate terpolymer matrix, Eudragit E, suitable for fibre formation. [84]

The solvent-free melt electrospinning (MES) method was developed to prepare a drug
delivery system with fast release of carvedilol (CAR), a drug with poor water solubility [85].
Cationic methacrylate copolymer of Eudragit E type was used as a fibre forming polymer
matrix. For comparison, ethanol-based electrospinning and melt extrusion (EX) methods
were used to produce samples that had the same composition as the melt electrospun system
(Figure 9). The drug release rate of the melt electrospun fibres was significantly higher than
that of the ground extrudate with the same composition due to the increased specific surface
area. The MES method also appears to produce structures with increased porosity (i.e., less
dense fibres within the structures. The authors suggested that this variation in morphology
results in the increased drug dissolution rate observed for the MES material due to increased
release media solvent accessibility to the drug loaded fibres.

Figure 9
Scanning electron microscopic image of (a) solvent based electrospun fibres
(10,000x magnifications) and (b) melt electrospun fibres (330x magnification) each
containing Eudragit E and 20% carvedilol. In vitro dissolution (c) of carvedilol (CAR).
MES: melt electrospun Eudragit E based fibres with 20% carvedilol content; SES: solventbased electrospun Eudragit E based fibres with 20% carvedilol content; EX, Eudragit E
based extrudates with 20% carvedilol; CAR, unprocessed crystalline carvedilol. (Reproduced
from reference [85] with permission).
14

Conclusions
The versatility of the techniques outlined in this review clearly indicates the advantages
associated with improving controlled release, delivery of poorly water soluble drugs, drug
stability and facilitating reduced drug dosage without compromising efficacy. It is obvious
from the above that innovative 3D fabrication approaches can be used to engineer delivery
systems that provide the desired performance through manipulating the assembly process for
a given material composition.

Combined with the ever increasing improvements being made in advanced fabrication
methods, it is inevitable that these approaches will become routine in the area of drug
delivery and may be the approach of choice to provide personalised drug delivery systems, on
demand.
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